A compound according to Formula I: ** Formula ** in which, R1 is H, or Me； L1 is -NR2-； -O-, or -CH2-； Cy is phenyl, or 5-9 membered fused monocyclic or bicyclic heteroaryl comprising 1 to 4 heteroatoms independently selected from N, O, and S； R2 is H, or C1-4 alkyl； R3 is H, halo, C1-4 alkyl optionally substituted with one or more halo, or C1-4 alkoxy optionally substituted with one or more halo； R4 is H or halo； R5 is -CN, halo or is -L2-R6 -L2 is absent, or is -C (>； = O) -, -C (>； = O) NR7, -NR7C (>； = O) -, -SO2-, -SO2NR7, or -NR7SO2-； R6 is H, or C1-6 alkyl optionally substituted with one or more independently selected R8 groups； R7 is H, or C1-4 alkyl； R8 is OH, CN, halo, or C1-4 alkoxy, La is absent, or is -C (>； = O) -, -C (>； = O) O- or -C (>； = O) NH-； Ra is: * H, * C1-4 alkyl optionally substituted with one or more independently selected Rb, * monocyclic C3-7 cycloalkyl optionally substituted with one or more independently selected Rc, or * 4-7 membered monocyclic heterocycloalkyl comprising one or more heteroatoms independently selected from O, N, and S, or * 5-6 membered monocyclic heteroaryl comprising one or more heteroatoms independently selected from O, N, and S； Rb is * halo, * CN, * OH, * C1-4 alkoxy, * C3-7 cycloalkyl, * 4-7 membered monocyclic heterocycloalkyl comprising one or more heteroatoms independently selected from O, N, and S (heterocycloalkyl is optionally substituted with one or more independently selected from halo, or oxo), * -SO2-C1-4 alkyl, or * -C (>； = O) NRb1Rb2 Rc is * halo, * CN, * OH, * C1-4 alkyl, * -C (>； = O) OH, or * -C (>； = O) NRc1Rc2； and each Rb1, Rb2, Rc1 and Rc2 is independently selected from H, and C1-4 alkyl, or a pharmaceutically acceptable salt, or a solvate, or a solvate of the pharmaceutically acceptable salt.Un compuesto de acuerdo con la Fórmula I:**Fórmula** en la que, R1 es H, o Me； L1 es -NR2-； -O-, o -CH2-； Cy es fenilo, o heteroarilo monocíclico o bicíclico fusionado de 5-9 miembros q
